Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Current Assets (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Current Assets for 8 consecutive years, with $132.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Assets fell 7.11% year-over-year to $132.8 million, compared with a TTM value of $132.8 million through Sep 2025, down 7.11%, and an annual FY2024 reading of $112.2 million, down 8.11% over the prior year.
  • Current Assets was $132.8 million for Q3 2025 at X4 Pharmaceuticals, up from $72.9 million in the prior quarter.
  • Across five years, Current Assets topped out at $175.4 million in Q2 2024 and bottomed at $52.6 million in Q2 2022.
  • Average Current Assets over 5 years is $108.6 million, with a median of $101.4 million recorded in 2021.
  • The sharpest move saw Current Assets soared 180.78% in 2023, then plummeted 58.42% in 2025.
  • Year by year, Current Assets stood at $87.9 million in 2021, then skyrocketed by 46.43% to $128.7 million in 2022, then dropped by 5.13% to $122.1 million in 2023, then fell by 8.11% to $112.2 million in 2024, then grew by 18.39% to $132.8 million in 2025.
  • Business Quant data shows Current Assets for XFOR at $132.8 million in Q3 2025, $72.9 million in Q2 2025, and $95.7 million in Q1 2025.